Gene therapy for cardiovascular disease: A case for cautious optimism

Hypertension

Volumn 38, Issue 5, 2001, Pages 1210-1216

  Khurana, Rohit ^a   Martin, John F ^a   Zachary, Ian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Atherosclerosis; Cardiovascular gene therapy; Hyperlipidemia

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GENE PRODUCT; HYPOXIA INDUCIBLE FACTOR 1; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RECOMBINANT PROTEIN; SCATTER FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN C; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANGIOGENESIS; ATHEROGENESIS; BLOOD PRESSURE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFICACY; ENDOTHELIUM CELL; FAMILIAL HYPERCHOLESTEROLEMIA; FIBRINOLYTIC THERAPY; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0035724762     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/hy1101.099483     Document Type: Conference Paper

References (74)

1. VEGF gene therapy: Stimulating angiogenesis or angiomagenesis
2. Direct myocardial revascularization and angiogenesis: How many patients might be eligible?
3. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for VEGF 121 improves myocardial perfusion and function in the ischaemic porcine heart
4. Therapeutic angiogenesis: A single intraarterial bolus of VEGF augments revascularization in a rabbit ischaemic hindlimb model
5. Adenovirus-mediated acidic FGF gene transfer induces angiogenesis in the nonischaemic rabbit heart
6. Angiogenic gene therapy for heart disease: A review of animal studies and clinical trials
7. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischaemia
8. Final results of the VIVA trial of rhVEGF human therapeutic angiogenesis
9. Efficacy of intracoronary or intravenous VEGF 165 in a pig model of chronic myocardial ischaemia
10. Intracoronary administration of recombinant fibroblast growth factor-2 in patients with severe coronary artery disease: Results of phase I
11. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of phase I randomized, double-blind, placebo-controlled trial
12. Therapeutic angiogenesis in cardiology using protein formulations
13. Regulations of vasculatropin/vascular endothelial growth factor bioavailability
14. Angiogenic gene therapy for heart disease: A review of animal studies and clinical trials
15. Clinical trials in coronary angiogenesis: Issues, problems, consensus
16. Haemodynamic effects of intracoronary VEGF delivery: Evidence of tachyphylaxis and NO dependence of response
17. Correction of hypertension by normalization of endothelial levels of fibroblast growth factor and nitric oxide synthase in spontaneously hypertensive rats
18. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
19. Vascular endothelial growth factor enhances atherosclerotic plaque progression
20. Still more debate over VEGF
21. Gene therapy with vascular endothelial growth factor for inoperable coronary disease
22. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty
23. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGFI21 cDNA to individuals with clinically significant coronary artery disease
24. Induction of neoangiogenesis in ischaemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
25. Cardiovascular gene therapy
26. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia and/or remodeling
27. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomized controlled trial
28. Gene therapy and vascular disease
29. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
30. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product
31. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells
32. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury
33. Apoptosis in the Atherosclerotic plaque: Quantitative and qualitative aspects
34. Is vascular smooth muscle cell proliferation beneficial?
35. Death receptors, intimal disease and gene therapy: Are therapies that modify cell fate moving too Fas?
36. Inhibition of neoiutimal cell bcl-x expression induces apoptosis and regression of vascular disease
37. Vascular protection: A novel, nonangiogenic cardiovascular role for vascular endothelial growth factor
38. Local adenovirus-mediated transfer of human eNOS reduces luminal narrowing after coronary angioplasty in pigs
39. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury
40. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries
41. Stent endothelialization. Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition
42. Effective treatment of familial hypercholesterolaemia in the mouse model using adeuovirus-mediated transfer of the VLDL receptor gene
43. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia
44. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia
45. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidaemias associated with apolipoprotein E and LDL receptor deficiencies in mice
46. Hepatic lipase gene therapy in hepatic-lipase deficient mice: Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium
47. Protein composition of Lp(a) lipoprotein from human plasma
48. Novel therapeutic strategy for atherosclerosis: Ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen expression
49. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolaemia in LDL-receptor deficient rabbits
50. High-density lipoprotein and atherosclerosis
51. Gene targets and approaches for raising HDL
52. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models
53. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type 1 reveals its key role in HDL metabolism
54. Apolipoprotein E deficiency in mice: Gene replacement and prevention of atherosclerosis using adenovirus vectors
55. Risk reduction associated with lowering systolic blood pressure: Review of clinical trial data
56. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats
57. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases
58. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats
59. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery
60. Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system
61. Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR
62. ACE antisense prevents altered renal vascular reactivity, but not high blood pressure in the SHR
63. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension
64. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse
65. Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats
66. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: Selective rescue of pulmonary hypertension in eNOS-deficient mice
67. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters
68. Identification of cis elements in the cardiac troponin T gene conferring specific expression in cardiac muscle of transgenic mice
69. Bone marrow cells regenerate infarcted myocardium
70. The use of adenoviral vectors for gene therapy and gene transfer in vivo
71. Mechanisms of delivery and local drug technologies
72. Gene delivery from a DNA controlled-release stent in porcine coronary arteries
73. Microsphere loaded monocytes are potential vectors for therapeutic arteriogenesis